Cialis® (over-the-counter ED medicine)Estac Vita Force (cold medicine)NESUGI (pollen relief medicine)イブアレジオンハイチオールドリエルエスタックシアリス®スルーラックガストールアネロンアレグラFXプレミアムSleep aidFoods with Function ClaimsDesignated Class 2 OTC medicineDrewell Your Rhythm DeepDrewell Your Rhythm RelaxDrewell Your Rhythm BeautyDrewell Natural SleepDrewell Natural Sleep αAntipyretic analgesicsAllergy medications for rhinitisL-cysteine and vitamin-related productsCold remediesED medicationsLaxatives, etc.Gastrointestinal medicationsMotion sickness medicationsCough suppressants and expectorantsBronWakefulness-promoting medicationsEstalon MochaBuscopanVitamin B supplementsS-Fight GoldTopical medicationsMemo AAnna Salve AceStomachics and refreshing agentsSS Gastrointestinal GranulesPharmaceutical Ingredient DictionaryRetailer Search
§04
Related companies
2 COMPANIES
Company name
Group
Parent
Subsidiary
Customer
Supplier
Alliance
Bank
Shareholder
Opella
Group
オペラグループ
Group
Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
33 EVENTS
In 1889, the national pharmacy law established pharmacies and drugstores nationwide, and the sales network of this pharmacy expanded to local areas by entering into wholesale agreements and exclusive contracts with wholesalers.
During the Taishō era that began in 1912, the efforts of the sixth president, Masakazu, were realized. The manufacturing base was relocated to Ebara in Tokyo (now Shinagawa Ward), and the company developed and manufactured both traditional Japanese and Western chemical drugs. A nationwide sales network was also established, and significant achievements began to be realized.
On October 29, 1927, the company was incorporated as "Hyo Taneya Pharmacy Co., Ltd." At that time, the company produced almost all of the popular over‑the‑counter drugs, and continued to produce products such as "Ninjin Ume Kō" that had been loved for 170 years since its Edo‑era founding.
In 1940, the company name was changed to the current trade name "SS Pharmaceutical." The president at that time was the sixth president, Masakazu Shirai.
In 1945, the Ebara factory was destroyed by air raids. Production was completely lost, and the company’s activities were halted until the end of the war.
On August 15, 1945, Japan surrendered unconditionally to the Allies. The Second World War ended, but the damage was severe: all production facilities and buildings were destroyed, and the company’s operations were suspended.
On the early morning of August 16, 1945, the company’s employees began reconstruction on the site of the former Ebara factory.
In December 1951, the company moved its headquarters from its long‑standing founding location in Yae‑su (now part of Chiyoda) to a newly built building in Ginza. The Osaka branch was also relocated and rebuilt at the same time.
In 1952, the "rabbit mark" was adopted as the unified logo for the SS chain. It began to be used as the brand mark for SS products and the company emblem.
In February 1958, a financial miscalculation led to a downturn in management, causing the then‑president, the sixth Masakazu Shirai, to step down. Tode Moriyoshi became president.
In 1963, the headquarters moved from Ginza to the front of Suiten‑gū in Nihonbashi. Construction of the Narita factory also began.
In 1964, the year of the Tokyo Olympics, the long‑awaited Narita factory completed its first phase of construction and began operations immediately, becoming the central hub of the company’s production activities.
In 1965, a new Osaka branch building was constructed to support nationwide sales expansion, and in November a new headquarters building was completed in Nihonbashi Hamacho.
In May 1972, the company launched a new L‑cysteine formulation, "Highi‑Tōru C."
May 1972 – Birth of Haitiol C
In 1985, the company released its second OTC pain reliever, "Ibuprofen," converting a medical drug into an OTC product, and SS Pharmaceutical’s development capabilities were highly praised.
In 1988, the company entered a capital and technology partnership with the American company Iba‑X, strengthening its development capabilities and establishing overseas bases.
In 1989, as Japan transitioned from the Showa to the Heisei era, the pharmaceutical industry had to consider global scale operations. The company continued its overseas expansion by partnering with the German company NUTRIKEM and investing in the Korean company Haedong Pharmaceutical, focusing on establishing overseas bases.
In 1997 (Heisei 9), Bayer Ingelheim Japan became the company's largest shareholder with a 9.2% stake.
In 1997 (Heisei 9), on the occasion of the company's 70th anniversary, a new corporate philosophy was adopted: "We wish for the health of all people, continue limitless exploration and challenge, and aim to be a trusted and beloved healthcare provider."
July 1998 – Renewal of Haitiol C
In August 1998 (Heisei 10), the Narita plant obtained ISO 14001 certification for its environmental management system.
In 2001 (Heisei 13), Bayer Ingelheim Japan's ownership exceeded 50%, and SS Pharmaceutical became part of Bayer Ingelheim.
In 2003 (Heisei 15), the company released a series of new products, including the new OTC drug "New Switch."
In 2005 (Heisei 17), the company divested its pharmaceutical business and was reborn as a company focused on consumer healthcare.
March 2006 – Release of Haitiol C Premier
In 2010 (Heisei 22), SS Pharmaceutical became a wholly-owned subsidiary of Bayer Ingelheim, enabling further synergy in new product development, talent development, and marketing, distribution, and sales strategy.
In 2011 (Heisei 23), the new structure of Bayer Ingelheim Japan Group began. Under Bayer Ingelheim Japan Co., Ltd., the domestic group companies share the same values and aim to grow together.
In the same year, "Alezion 10" was launched. It was the first OTC medication in Japan to contain the Bayer Ingelheim-developed active ingredient epinastine hydrochloride. With high efficacy, low drowsiness, and a once‑daily dosage of one tablet, it differentiated itself and significantly contributed to consumers' self‑medication.
In March of the same year, the Great East Japan Earthquake damaged the factory, but management and employees united to support the affected areas and employees. Additional support from the entire Bayer Ingelheim Group helped overcome the crisis.
In January 2017 (Heisei 29), the exchange of Sanofi's animal health business with Bayer Ingelheim's consumer healthcare (CHC) business was completed, making SS Pharmaceutical a member of the Sanofi Japan Group as of January 1 of that year.
In December of the same year, the headquarters moved from Nihonbashi Hamacho to the same Tokyo Opera City Tower as Sanofi Japan, aiming to create further synergy as part of Sanofi Japan Group's CHC business.
In April 2025, SS Pharmaceutical completed the spin‑off of the global company Opella. (Opella), and under the new structure, it began operating. SS Pharmaceutical, a former subsidiary of French pharmaceutical company Sanofi, became a 100% subsidiary of the Opella Group, which operates in self‑care across more than 100 countries.
§07
News
37 ARTICLES
Transfer of Allegra Manufacturing and Sales Approval and Change of Sales Structure
SS Pharmaceutical received the transfer of manufacturing and sales approval for "Allegra FX", "Allegra FX Junior", and "Allegra FX Premium" from Sanofi on November 2. From that date, sales of "Allegra FX" and "Allegra FX Junior" began, and "Allegra FX Premium" will continue to be sold. The company will strive to ensure stable supply as the manufacturer and will continue to provide information to relevant institutions and promote appropriate use.
New Estac Commercial Featuring Kento Kaku to Air Nationwide
Estac, SS Pharmaceutical’s comprehensive cold medicine brand, will air a new 15-second TV commercial titled “The Strength to Bounce Back. Estac” featuring Kento Kaku nationwide (excluding some areas) from October 26, 2026. The commercial introduces Estac EX Neo, which is effective against all 11 cold symptoms, and Estac Vita Force, launched in September 2026. Thirty-second commercials highlighting the features of each product will also be released and distributed in stages on the brand website, the official YouTube channel, and through digital advertising.
SS Pharmaceutical Begins Selling Cialis® on Amazon.co.jp
SS Pharmaceutical Co., Ltd. has begun online sales of Cialis®, an over-the-counter medicine for erectile dysfunction, on Amazon.co.jp. Starting October 20, 2026, customers can safely access genuine products, with a system in place that allows them to purchase after consulting a pharmacist.
Pillow Mist “NESUGI” Wins the 2026 Good Design Award
Pillow mist “NESUGI,” whose development was supported by SSP, won the 2026 Good Design Award. It was recognized for creating a pleasant sleep environment with a fragrance made from pollen-producing cedar trees and for contributing to a fundamental solution to the pollen problem by promoting the use of cedar.
SS Pharmaceutical Recertified as a B Corp Under B Lab’s New Standards
SS Pharmaceutical Co., Ltd. (headquartered in Shinjuku, Tokyo) has obtained B Corp™ recertification under B Lab’s New Standards V2, with Opera responsible for its business in Japan. This recertification further strengthens the leadership of its initial B Corp certification, which it obtained in April 2025.
Estac Vita Force, a Combination Cold Medicine Containing Vitamins C and B1, Launches on September 8
SS Pharmaceutical began selling Estac Vita Force, a combination cold medicine containing five active ingredients plus vitamins C and B1, on September 8. The product is formulated to relieve all 11 cold symptoms and support recovery from a cold.
Donation for the 2026 Kumamoto Earthquake
SS Pharmaceutical has decided to donate 5 million yen to the Japanese Red Cross Society to support relief efforts for those affected and recovery in the disaster-stricken areas.
SS Pharmaceutical to Begin Nationwide Launch of Cialis®, Japan’s First Over-the-Counter ED Medication
SS Pharmaceutical Co., Ltd. will begin nationwide sales of Cialis®, Japan’s first over-the-counter medication for erectile dysfunction (ED), on August 31, 2026. At participating stores with pharmacists on staff, the company will establish a sales system that supports access to authentic products and raise awareness of ED as a health issue that can be addressed.
SSP Co., Ltd. and Morinaga & Co., Ltd. Launch Cross-Mentoring Program to Support Women's Careers
As part of the BeliEVE PROJECT, SSP Co., Ltd. is partnering with Morinaga & Co., Ltd. to implement a mentoring program aimed at supporting the careers of female employees. The two companies share common values in the fields of pharmaceuticals and food, and aim to broaden career perspectives through opportunities for dialogue across company lines.
SS Pharmaceutical Begins Selling Cialis® as Japan’s First Over-the-Counter ED Drug
SS Pharmaceutical Co., Ltd. will start selling Cialis® at selected stores staffed by pharmacists from July 31, 2026, and plans to roll out nationwide from August 31. The OTC availability will create an environment where people struggling with ED can receive appropriate care under pharmacist guidance.
§08
Public records
GOV
National Tax Agency basic information8010001034749
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
エスエス製薬株式会社
Trade name (kana)
エスエスセイヤク
Name in English
Corporation type
301
Address
〒160-0023 東京都新宿区西新宿3丁目20番2号
Postal code
1600023
Prefecture code
13
City code
104
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-04-18
Change date
2018-03-07
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
2313309
METI gBizINFO8010001034749
Source: gBizINFO (Ministry of Economy, Trade and Industry)